Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3

L. Kemény, Lovisa Berggren, Martin Dossenbach, Yves Dutronc, Carle Paul

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. Materials and methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50 mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized by baseline Psoriasis Area and Severity Index (PASI <20 and ≥20). Efficacy was evaluated by percentage reaching PASI 75, 90, 100, and absolute PASI ≤5, ≤2, and ≤1. Results: Significantly more patients with PASI ≥20 (vs. PASI <20) were male and had higher body weight. After 12 weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI 75, 90, 100, and absolute PASI ≤5, ≤2, ≤1. Fewer PASI ≥20 vs. PASI <20 patients across treatments reached PASI ≤5, ≤2, and ≤1 at week 12. Efficacy was maintained during 156 weeks of ixekizumab treatment with no differences between groups. The IXEQ2W safety profile was similar between groups except for injection-site reactions (significantly higher in PASI <20). Conclusions: Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalJournal of Dermatological Treatment
DOIs
Publication statusAccepted/In press - Jun 11 2018

Fingerprint

LY2439821
Psoriasis
Safety
Placebos
Body Weight
Clinical Trials

Keywords

  • Ixekizumab
  • psoriasis
  • Psoriasis Area and Severity Index
  • severity

ASJC Scopus subject areas

  • Dermatology

Cite this

Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity : results from UNCOVER-2 and UNCOVER-3. / Kemény, L.; Berggren, Lovisa; Dossenbach, Martin; Dutronc, Yves; Paul, Carle.

In: Journal of Dermatological Treatment, 11.06.2018, p. 1-8.

Research output: Contribution to journalArticle

@article{82b5eae97ffe478c81a87cafae51c035,
title = "Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3",
abstract = "Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. Materials and methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50 mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized by baseline Psoriasis Area and Severity Index (PASI <20 and ≥20). Efficacy was evaluated by percentage reaching PASI 75, 90, 100, and absolute PASI ≤5, ≤2, and ≤1. Results: Significantly more patients with PASI ≥20 (vs. PASI <20) were male and had higher body weight. After 12 weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI 75, 90, 100, and absolute PASI ≤5, ≤2, ≤1. Fewer PASI ≥20 vs. PASI <20 patients across treatments reached PASI ≤5, ≤2, and ≤1 at week 12. Efficacy was maintained during 156 weeks of ixekizumab treatment with no differences between groups. The IXEQ2W safety profile was similar between groups except for injection-site reactions (significantly higher in PASI <20). Conclusions: Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels.",
keywords = "Ixekizumab, psoriasis, Psoriasis Area and Severity Index, severity",
author = "L. Kem{\'e}ny and Lovisa Berggren and Martin Dossenbach and Yves Dutronc and Carle Paul",
year = "2018",
month = "6",
day = "11",
doi = "10.1080/09546634.2018.1473551",
language = "English",
pages = "1--8",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity

T2 - results from UNCOVER-2 and UNCOVER-3

AU - Kemény, L.

AU - Berggren, Lovisa

AU - Dossenbach, Martin

AU - Dutronc, Yves

AU - Paul, Carle

PY - 2018/6/11

Y1 - 2018/6/11

N2 - Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. Materials and methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50 mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized by baseline Psoriasis Area and Severity Index (PASI <20 and ≥20). Efficacy was evaluated by percentage reaching PASI 75, 90, 100, and absolute PASI ≤5, ≤2, and ≤1. Results: Significantly more patients with PASI ≥20 (vs. PASI <20) were male and had higher body weight. After 12 weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI 75, 90, 100, and absolute PASI ≤5, ≤2, ≤1. Fewer PASI ≥20 vs. PASI <20 patients across treatments reached PASI ≤5, ≤2, and ≤1 at week 12. Efficacy was maintained during 156 weeks of ixekizumab treatment with no differences between groups. The IXEQ2W safety profile was similar between groups except for injection-site reactions (significantly higher in PASI <20). Conclusions: Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels.

AB - Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. Materials and methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W), or 50 mg etanercept (ETN) biweekly for 12 weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized by baseline Psoriasis Area and Severity Index (PASI <20 and ≥20). Efficacy was evaluated by percentage reaching PASI 75, 90, 100, and absolute PASI ≤5, ≤2, and ≤1. Results: Significantly more patients with PASI ≥20 (vs. PASI <20) were male and had higher body weight. After 12 weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI 75, 90, 100, and absolute PASI ≤5, ≤2, ≤1. Fewer PASI ≥20 vs. PASI <20 patients across treatments reached PASI ≤5, ≤2, and ≤1 at week 12. Efficacy was maintained during 156 weeks of ixekizumab treatment with no differences between groups. The IXEQ2W safety profile was similar between groups except for injection-site reactions (significantly higher in PASI <20). Conclusions: Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in patients with different baseline psoriasis severity levels.

KW - Ixekizumab

KW - psoriasis

KW - Psoriasis Area and Severity Index

KW - severity

UR - http://www.scopus.com/inward/record.url?scp=85048365345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048365345&partnerID=8YFLogxK

U2 - 10.1080/09546634.2018.1473551

DO - 10.1080/09546634.2018.1473551

M3 - Article

C2 - 29726739

AN - SCOPUS:85048365345

SP - 1

EP - 8

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

ER -